





or pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition including a compound according to claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.

~~8. A method of treatment of a condition selected from the group consisting of Type I diabetes, Type II diabetes, hyperglycemia, low glucose tolerance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, abdominal obesity, glaucoma, hypertension, atherosclerosis and its sequelae, retinopathy, nephropathy, neuropathy, osteoporosis, osteoarthritis, dementia, depression, psychiatric disorders, Cushing's Disease, and Cushing's syndrome in a mammal, the method comprising administering an effective amount of a compound according to claim 1.~~

~~9. A method according to claim 8 wherein the condition is type II diabetes.~~

~~10. The method of claim 8, wherein the compound is administered in combination with an adjuvant~~.

~~11. The method of claim 10, wherein the adjuvant is selected from the group consisting of dipeptidyl peptidase-IV (DP-IV) inhibitors; (b) insulin sensitizing agents; (c) insulin and insulin mimetics; (d) sulfonylureas and other insulin secretagogues; (e) alpha-glucosidase inhibitors; (f) GLP-1, GLP-1 analogs, and GLP-1 receptor agonists; and combinations thereof.~~

~~12. The method of claim 11, wherein the insulin sensitizing agents are selected from the group consisting of (i) PPAR-gamma agonists, (ii) PPAR-alpha agonists, (iii) PPAR-alpha/gamma dual agonists, (iv) biguanides, and combinations thereof.~~

~~13~~8. A pharmaceutical composition including a compound according to claim 6 and a pharmaceutically acceptable diluent, excipient or carrier.

~~14. A method of treatment of a condition selected from the group consisting of Type I diabetes, Type II diabetes, hyperglycemia, low glucose tolerance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, obesity, abdominal obesity, glaucoma, hypertension, atherosclerosis and its sequelae, retinopathy, nephropathy, neuropathy, osteoporosis, ostcoarthritis, dementia, depression, psychiatric disorders, Cushing's Disease, and Cushing's syndrome, in a mammal, the method comprising administering an effective amount of a compound according to claim 6.~~

~~15. A method according to claim 6 wherein the condition is type II diabetes.~~

~~16. The method of claim 6, wherein the compound is administered in combination with an adjuvant.~~

~~17. The method of claim 6, wherein the adjuvant is selected from the group consisting of dipeptidyl peptidase-IV (DP-IV) inhibitors; (b) insulin sensitizing agents; (c) insulin and insulin mimetics; (d) sulfonylureas and other insulin secretagogues; (e) alpha-glucosidase inhibitors; (f) GLP-1, GLP-1 analogs, and GLP-1 receptor agonists; and combinations thereof.~~

18. The method of claim 6, wherein the insulin sensitizing agents are selected from the group consisting of (i) PPAR-gamma-agonists, (ii) PPAR-alpha-agonists, (iii) PPAR-alpha/gamma-dual agonists, (iv) biguanides, and combinations thereof.